Citizens JMP lowered the firm’s price target on Bicycle Therapeutics (BCYC) to $22 from $26 and keeps an Outperform rating on the shares. Bicycle reported Q1 results and provided corporate milestones, including the initiation of the Phase 1/2 Duravelo-3 trial in NECTIN4-amplified breast cancer, which will enroll roughly 60 patients, the analyst tells investors in a research note. The firm continues to believe Bicycle shares represent a unique investment opportunity.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCYC:
- Bicycle Therapeutics Reports Q1 2025 Progress and Financials
- Bicycle Therapeutics price target lowered to $15 from $40 at Barclays
- Bicycle Therapeutics: Promising Advancements and Strong Financial Position Justify Buy Rating
- Promising Developments in Bicycle Therapeutics’ Pipeline Bolster Buy Rating
- Bicycle Therapeutics reports Q1 EPS (88c), consensus (81c)